Aclarion, Inc. ((ACON)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aclarion, Inc. is conducting a multi-center randomized clinical study titled ‘A Multi-Center Randomized Clinical Study of the NOCISCAN MR Spectroscopy (MRS) in Patients Treated for Discogenic Low Back Pain.’ The study aims to assess the safety and efficacy of NOCISCAN, a Software as a Service (SaaS) tool utilizing Magnetic Resonance (MR) spectroscopy to differentiate between painful and nonpainful discs in the lumbar spine. This research is significant as it could improve surgical outcomes for patients suffering from discogenic low back pain.
The intervention being tested is NOCISCAN, which is used pre-operatively to generate Nocigram reports. These reports help physicians decide on the appropriate surgical treatment, such as Fusion or Total Disc Replacement (TDR), by distinguishing between painful and nonpainful discs.
The study is designed as an observational cohort with a prospective time perspective. It involves two groups: one blinded to the NOCISCAN results and the other unblinded. The primary purpose is to compare surgical outcomes between these groups based on the Nocigram reports generated before treatment.
The study began on October 22, 2024, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on September 12, 2025, indicating ongoing recruitment and progress.
This clinical study update could positively impact Aclarion’s stock performance and investor sentiment by demonstrating the potential of NOCISCAN to enhance surgical decision-making and outcomes. As the healthcare industry increasingly adopts innovative technologies, Aclarion’s advancements could position it favorably against competitors.
The study is ongoing, and further details are available on the ClinicalTrials portal.